查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1728164

HPV 檢測和巴氏試驗市場－全球產業規模、佔有率、趨勢、機會和預測、細分測試類型、按應用、按最終用戶、按地區和競爭情況，2020-2030 年預測

HPV Testing and Pap Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented Test Type, By Application, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球 HPV 檢測和巴氏試驗市場價值為 42.6 億美元，預計到 2030 年將達到 80.1 億美元，預測期內複合年成長率為 11.10%。隨著世界各地的醫療保健系統更加關注女性健康和子宮頸癌的預防，該市場正在強勁擴張。人類乳突病毒 (HPV) 是導致子宮頸癌的主要原因，推動了對 HPV 檢測和巴氏抹片等早期檢測工具的需求。市場成長受到公眾意識不斷提高、政府篩檢計畫以及 HPV DNA 檢測和液基細胞學等技術創新的支持，這些技術具有更高的靈敏度和更好的診斷準確性。這些進步增強了早期檢測能力，減少了假陰性，並改善了患者的治療效果。增加醫療保健投資、透過即時診斷方法擴大篩檢管道以及優先採取預防性保健措施也做出了重大貢獻。 COVID-19 疫情進一步加速了高效、可擴展診斷解決方案的採用，增強了可靠檢測工具在全球醫療保健系統中的價值。

市場概覽
預測期 2026-2030
2024年市場規模 42.6億美元
2030年市場規模 80.1億美元
2025-2030 年複合年成長率 11.10%
成長最快的領域 醫院/診所
最大的市場 北美洲

關鍵市場促進因素

子宮頸癌發病率和死亡率上升

主要市場挑戰

醫療服務取得機會有限

主要市場趨勢

HPV DNA 檢測的快速普及

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球HPV檢測與巴氏試驗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依檢測類型（HPV 檢測、巴氏試驗、聯合檢測）
    • 按應用（子宮頸癌篩檢測試、頭頸癌篩檢測試、其他應用）
    • 依最終使用者（醫院/診所、診斷中心、照護端/自我採樣）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美HPV檢測與巴氏試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲HPV檢測與巴氏試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區 HPV 檢測與巴氏試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美HPV檢測與巴氏試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 HPV 檢測和巴氏試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Arbor Vita Corporation
  • Danaher Corporation
  • Seegene Inc.
  • Becton, Dickinson and Company
  • TruScreen
  • Abbott Laboratories
  • Hologic Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche Ltd
  • OncoHealth Corporation

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16329

The Global HPV Testing and Pap Test Market was valued at USD 4.26 billion in 2024 and is projected to reach USD 8.01 billion by 2030, growing at a CAGR of 11.10% during the forecast period. This market is witnessing robust expansion as healthcare systems around the world focus more on women's health and the prevention of cervical cancer. Human Papillomavirus (HPV), a primary cause of cervical cancer, has driven demand for early detection tools such as HPV testing and Pap smears. Market growth is being supported by rising public awareness, government screening programs, and technological innovations like HPV DNA testing and liquid-based cytology, which offer higher sensitivity and improved diagnostic accuracy. These advancements enhance early detection, reduce false negatives, and improve patient outcomes. Increasing healthcare investments, expanding screening access through point-of-care methods, and the prioritization of preventive health measures are also contributing significantly. The COVID-19 pandemic further accelerated the adoption of efficient and scalable diagnostic solutions, reinforcing the value of reliable testing tools in global healthcare systems.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.26 Billion
Market Size 2030USD 8.01 Billion
CAGR 2025-203011.10%
Fastest Growing SegmentHospitals/Clinics
Largest MarketNorth America

Key Market Drivers

Rising Cervical Cancer Incidence and Mortality Rates

The growing incidence of cervical cancer, especially in low- and middle-income countries, is a primary factor driving the demand for HPV and Pap testing. Many of these regions face high mortality rates due to late diagnoses and limited access to routine screenings. According to the WHO, in 2020, around 604,000 women were diagnosed with cervical cancer globally, with 342,000 deaths. Given that a majority of these cases are linked to HPV infections, early screening using HPV tests and Pap smears has become vital. Governments and health organizations are expanding screening programs to address this urgent public health issue, with efforts ranging from public education campaigns to infrastructure development and subsidized testing services. The increasing focus on early detection as a means of reducing cervical cancer mortality is expected to significantly boost the adoption of HPV and Pap tests across diverse healthcare settings.

Key Market Challenges

Limited Access to Healthcare Services

Access to healthcare services remains a significant barrier to the widespread adoption of HPV and Pap testing, particularly in underserved and rural areas. In many regions, inadequate healthcare infrastructure, limited medical personnel, long travel distances to healthcare facilities, and affordability issues prevent regular screenings. Women in these settings are often unable to receive timely diagnostic evaluations, increasing the risk of undetected cervical abnormalities progressing to cancer. These systemic challenges reduce overall screening rates and limit the effectiveness of national and global cancer prevention efforts. Addressing these access issues is essential for ensuring that life-saving tests reach the populations most at risk.

Key Market Trends

Rapid Adoption of HPV DNA Testing

The increasing use of HPV DNA testing is a major trend reshaping the HPV and Pap test market. This advanced method offers superior sensitivity and specificity in identifying high-risk HPV strains that are most likely to cause cervical cancer. As awareness of its diagnostic advantages grows, healthcare providers are increasingly integrating HPV DNA tests into routine screening protocols. This trend is further accelerated by the rising demand for early and accurate detection tools, especially in preventive oncology. The shift towards HPV DNA testing is enhancing the reliability of screening programs and contributing to better patient outcomes by identifying risk at an earlier stage.

Key Market Players

  • Arbor Vita Corporation
  • Danaher Corporation
  • Seegene Inc.
  • Becton, Dickinson and Company
  • TruScreen
  • Abbott Laboratories
  • Hologic Inc.
  • Qiagen N.V.
  • F. Hoffmann-La Roche Ltd
  • OncoHealth Corporation

Report Scope:

In this report, the Global HPV Testing and Pap Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

HPV Testing and Pap Test Market, By Test Type:

  • HPV Test
  • Pap Test
  • Co-testing

HPV Testing and Pap Test Market, By End User:

  • Hospitals/Clinics
  • Diagnostic Centers
  • Point-of-Care/Self-sampling

HPV Testing and Pap Test Market, By Application:

  • Cervical Cancer Screening Test
  • Head and Neck Cancer Screening Test
  • Other Applications

HPV Testing and Pap Test Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global HPV Testing and Pap Test Market.

Available Customizations:

Global HPV Testing and Pap Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global HPV Testing and Pap Test Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (HPV Test, Pap Test, Co-testing)
    • 5.2.2. By Application (Cervical Cancer Screening Test, Head and Neck Cancer Screening Test, Other Applications)
    • 5.2.3. By End User (Hospitals/Clinics, Diagnostic Centers, Point-of-Care/Self-sampling)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America HPV Testing and Pap Test Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States HPV Testing and Pap Test Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico HPV Testing and Pap Test Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada HPV Testing and Pap Test Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe HPV Testing and Pap Test Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France HPV Testing and Pap Test Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany HPV Testing and Pap Test Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom HPV Testing and Pap Test Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy HPV Testing and Pap Test Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain HPV Testing and Pap Test Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific HPV Testing and Pap Test Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China HPV Testing and Pap Test Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India HPV Testing and Pap Test Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea HPV Testing and Pap Test Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan HPV Testing and Pap Test Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia HPV Testing and Pap Test Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America HPV Testing and Pap Test Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil HPV Testing and Pap Test Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina HPV Testing and Pap Test Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia HPV Testing and Pap Test Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa HPV Testing and Pap Test Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa HPV Testing and Pap Test Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia HPV Testing and Pap Test Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE HPV Testing and Pap Test Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Arbor Vita Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Danaher Corporation
  • 15.3. Seegene Inc.
  • 15.4. Becton, Dickinson and Company
  • 15.5. TruScreen
  • 15.6. Abbott Laboratories
  • 15.7. Hologic Inc.
  • 15.8. Qiagen N.V.
  • 15.9. F. Hoffmann-La Roche Ltd
  • 15.10. OncoHealth Corporation

16. Strategic Recommendation

17. About Us & Disclaimer